"I am highly honored by the great privilege of having Dr. Sidransky lead the company into the future as its Chairman" said James Martell, President and CEO of Champions Biotechnology. "Dr. Sidransky is a creative, out-of-the box thinker with wide-ranging academic and business background and extensive contacts within the pharmaceutical industry, academia and government. He will provide the vision, direction, drive and inspiration to grow our Company into what we hope will be one of the leading biotechnology players in the world, in the fight against disease."
Champions Biotechnology is actively engaged, as stated in the Company's most recent 10-QSB filing, in pursuit of long term funding, additional opportunities to grow and strengthen the Company, development of management team, selection and appointment of new members to the Board of Directors and formation of a Scientific Advisory Board. The Company looks forward to reporting updates regarding any material events and corporate changes in the future.
About Champions Biotechnology, Inc.
Champions Biotechnology is a twenty two year old publicly traded company that beginning in January 2007, changed its business direction to focus on biotechnology. The Company is engaged in the acquisition and early stage development of a portfolio of new therapeutic drug candidates, in the acquisition and development of novel technologies and in providing administrative services in the field of oncology that the Company hopes will improve methods of and approaches to disease treatment.
Champions Biotechnology plans to develop a portfolio of new therapeutic
drug candidates through p
|SOURCE Champions Biotechnology, Inc.|
Copyright©2007 PR Newswire.
All rights reserved